Talkmed Group Stock | 5G3.SI | SG2G61000003 | | August 2025

Date	Talkmed Group Price
7/30/2025	0.45 SGD
7/29/2025	0.45 SGD
7/28/2025	0.45 SGD
7/24/2025	0.46 SGD
7/22/2025	0.45 SGD
7/21/2025	0.45 SGD
7/18/2025	0.46 SGD
7/16/2025	0.46 SGD
7/14/2025	0.46 SGD
7/10/2025	0.46 SGD
7/7/2025	0.46 SGD
7/4/2025	0.46 SGD
7/3/2025	0.45 SGD

Date	Talkmed Group Revenue	Talkmed Group EBIT	Talkmed Group Net Income
2024	78.18 M SGD	32.46 M SGD	43.79 M SGD
2023	83.79 M SGD	39.04 M SGD	32.18 M SGD
2022	76.6 M SGD	39.21 M SGD	30.55 M SGD
2021	60.75 M SGD	26.94 M SGD	25.12 M SGD
2020	62.14 M SGD	27.32 M SGD	22.77 M SGD
2019	75.92 M SGD	41.21 M SGD	35.75 M SGD
2018	61.28 M SGD	34.16 M SGD	28.91 M SGD
2017	61.36 M SGD	39.6 M SGD	32.04 M SGD
2016	68.91 M SGD	48.39 M SGD	37.39 M SGD
2015	65.72 M SGD	47.94 M SGD	37.33 M SGD
2014	63.17 M SGD	46.45 M SGD	38.53 M SGD
2013	56.27 M SGD	35.81 M SGD	28.21 M SGD
2012	51.86 M SGD	38.49 M SGD	31.98 M SGD
2011	49.14 M SGD	39.23 M SGD	32.6 M SGD
2010	48.34 M SGD	39.01 M SGD	32.43 M SGD

	Revenue	EBIT	Net Income
2010	48.34 M SGD	39.01 M SGD	32.43 M SGD
2011	49.14 M SGD	39.23 M SGD	32.6 M SGD
2012	51.86 M SGD	38.49 M SGD	31.98 M SGD
2013	56.27 M SGD	35.81 M SGD	28.21 M SGD
2014	63.17 M SGD	46.45 M SGD	38.53 M SGD
2015	65.72 M SGD	47.94 M SGD	37.33 M SGD
2016	68.91 M SGD	48.39 M SGD	37.39 M SGD
2017	61.36 M SGD	39.6 M SGD	32.04 M SGD
2018	61.28 M SGD	34.16 M SGD	28.91 M SGD
2019	75.92 M SGD	41.21 M SGD	35.75 M SGD
2020	62.14 M SGD	27.32 M SGD	22.77 M SGD
2021	60.75 M SGD	26.94 M SGD	25.12 M SGD
2022	76.6 M SGD	39.21 M SGD	30.55 M SGD
2023	83.79 M SGD	39.04 M SGD	32.18 M SGD
2024	78.18 M SGD	32.46 M SGD	43.79 M SGD

2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
48	49	51	56	63	65	68	61	61	75	62	60	76	83	78
-	2.08	4.08	9.80	12.50	3.17	4.62	-10.29	-	22.95	-17.33	-3.23	26.67	9.21	-6.02
95.83	93.88	90.20	82.14	73.02	70.77	67.65	75.41	75.41	61.33	74.19	56.67	60.53	55.42	58.97
0	0	0	0	0	0	0	0	0	0	0	34	46	0	0
32	32	31	28	38	37	37	32	28	35	22	25	30	32	43
-	-	-3.13	-9.68	35.71	-2.63	-	-13.51	-12.50	25.00	-37.14	13.64	20.00	6.67	34.38
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1.31	1.31	1.31	1.31	1.3	1.31	1.31	1.31	1.31	1.31	1.32	1.33	1.33	1.33	1.34
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

10.46	12.36	16.75	24.89	50.9	49.56	64	71.05	73.99	80.7	79.43	82.16	81.24	89.9	82.78
5.25	5.56	6.04	6.83	9.01	9.17	6.43	8.37	8.31	11.42	9.5	8.37	11.02	10.87	12.68
10	10	0	570	130	480	266	269	407	845	792	637	806	571	757
0	0	0	0	0	0	0.06	0.17	0.28	0.86	1	0.77	1.28	1.42	1.31
0	0	0	70	41	103	178	273	648	610	584	486	444	335	342
15.72	17.93	22.79	32.36	60.07	59.31	70.93	80.13	83.64	94.43	91.31	92.42	94.78	103.1	97.86
0	0	0	0.05	0.03	0.52	0.51	0.67	4.23	8.74	6.17	8.51	10.08	9.66	8.72
0	0	0	0	0	8.64	5	4.54	3.4	2.89	7.11	7.44	3.7	2.81	0.15
0	0	0	0	0	15	14	0	0	0	0	410	606	222	61
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	9	4	18	25	0	0	0	0
0	0	0	0.05	0.03	9.17	5.53	5.22	7.64	11.64	13.31	16.36	14.38	12.69	8.92
15.72	17.93	22.79	32.41	60.1	68.49	76.46	85.36	91.27	106.07	104.62	108.79	109.17	115.79	106.79

0	0	0	2.31	22.27	22.27	22.27	22.27	22.27	22.44	23.91	24.51	25.12	25.81	26.63
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7.52	10.12	12.1	10.49	27.53	34.04	41.3	50.69	51.99	60.96	59.32	65.11	63.74	63.9	56.88
0	0	0	0	0	0	0	-632	-495	-290	213	564	-148	413	450
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7.52	10.12	12.1	12.8	49.8	56.32	63.58	72.33	73.77	83.1	83.43	90.18	88.71	90.12	83.96
1.25	0.89	0.76	8.05	1.33	1.51	1.74	0.3	0.52	1.28	0.4	0.63	0.8	1.77	2.23
0.35	0.23	3.42	4.48	0.91	1.28	2.02	2.56	3.94	3.35	4.15	3.4	4.68	7.45	7.56
6.6	6.69	6.52	7.09	8.06	8.3	8.57	8.65	8.28	10.36	11.07	8.25	12.04	13.33	11.82
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	1.77	1.79	1.98	1.85	4.73	4.99
8.2	7.81	10.7	19.62	10.3	11.1	12.32	11.5	12.74	16.77	17.41	14.25	19.38	27.28	26.61
0	0	0	0	0	0	0	0	0	2.12	2.69	4.49	5.23	4.45	3.73
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0.03	0.03	1.34	5.19	5.5	5.76	2.55	2.68	0	0
0	0	0	0	0	0.03	0.03	1.34	5.19	7.62	8.45	7.04	7.92	4.45	3.73
8.2	7.81	10.7	19.62	10.3	11.13	12.35	12.85	17.92	24.38	25.87	21.29	27.3	31.73	30.33
15.72	17.93	22.8	32.42	60.1	67.45	75.93	85.18	91.69	107.49	109.3	111.46	116.01	121.85	114.3

2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
39	39	38	35	46	45	45	38	34	41	24	27	36	37
0	0	0	0	0	0	0	0	0	3	3	2	2	2
0	0	0	0	0	0	0	0	0	0	0	0	0	0
-5	-7	-4	0	-18	-7	-3	-9	-5	-9	-3	-7	-5	0
0	0	0	0	0	2	2	1	0	0	6	0	2	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0
6	6	6	7	7	8	8	8	7	6	5	9	5	7
33	31	34	35	27	40	44	30	30	35	31	23	37	41
0	0	0	0	0	0	0	0	-3	-2	-1	0	-4	0
0	0	0	0	0	-12	0	0	-3	-2	-8	-1	-5	0
0	0	0	0	0	-11	0	0	0	0	-6	-1	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	-1	-1	-2	-2	-2
0	0	0	0	0	0	0	0	0	0	0	0	0	0
-30	-30	-30	-27	-1	-29	-30	-23	-23	-27	-24	-18	-33	-31
0	0	0	0	-1	1	0	1	4	1	2	2	0	2
-30	-30	-30	-27	-21	-30	-30	-25	-28	-27	-25	-19	-31	-31
3	1	4	8	26	-1	14	7	2	6	-1	2	-1	9
33.49	31.9	34.39	35.64	27.53	39.81	44.56	30.46	26.15	33.76	29.32	22.39	32.97	41.02
0	0	0	0	0	0	0	0	0	0	0	0	0	0

Talkmed Group Gross margin	Talkmed Group Profit margin	Talkmed Group EBIT margin	Talkmed Group Profit margin
2024	61.31 %	41.52 %	56.01 %
2023	61.31 %	46.59 %	38.4 %
2022	61.31 %	51.18 %	39.88 %
2021	57.12 %	44.34 %	41.34 %
2020	61.31 %	43.97 %	36.64 %
2019	61.31 %	54.29 %	47.09 %
2018	61.31 %	55.74 %	47.18 %
2017	61.31 %	64.54 %	52.21 %
2016	61.31 %	70.21 %	54.26 %
2015	61.31 %	72.94 %	56.81 %
2014	61.31 %	73.54 %	61 %
2013	61.31 %	63.64 %	50.13 %
2012	61.31 %	74.22 %	61.67 %
2011	61.31 %	79.83 %	66.34 %
2010	61.31 %	80.7 %	67.09 %

	Gross margin	EBIT margin	Profit margin
2010	61.31 %	80.7 %	67.09 %
2011	61.31 %	79.83 %	66.34 %
2012	61.31 %	74.22 %	61.67 %
2013	61.31 %	63.64 %	50.13 %
2014	61.31 %	73.54 %	61 %
2015	61.31 %	72.94 %	56.81 %
2016	61.31 %	70.21 %	54.26 %
2017	61.31 %	64.54 %	52.21 %
2018	61.31 %	55.74 %	47.18 %
2019	61.31 %	54.29 %	47.09 %
2020	61.31 %	43.97 %	36.64 %
2021	57.12 %	44.34 %	41.34 %
2022	61.31 %	51.18 %	39.88 %
2023	61.31 %	46.59 %	38.4 %
2024	61.31 %	41.52 %	56.01 %

Date	Talkmed Group Sales per Share	Talkmed Group EBIT per share	Talkmed Group Earnings per Share
2024	0.06 SGD	0.02 SGD	0.03 SGD
2023	0.06 SGD	0.03 SGD	0.02 SGD
2022	0.06 SGD	0.03 SGD	0.02 SGD
2021	0.05 SGD	0.02 SGD	0.02 SGD
2020	0.05 SGD	0.02 SGD	0.02 SGD
2019	0.06 SGD	0.03 SGD	0.03 SGD
2018	0.05 SGD	0.03 SGD	0.02 SGD
2017	0.05 SGD	0.03 SGD	0.02 SGD
2016	0.05 SGD	0.04 SGD	0.03 SGD
2015	0.05 SGD	0.04 SGD	0.03 SGD
2014	0.05 SGD	0.04 SGD	0.03 SGD
2013	0.04 SGD	0.03 SGD	0.02 SGD
2012	0.04 SGD	0.03 SGD	0.02 SGD
2011	0.04 SGD	0.03 SGD	0.02 SGD
2010	0.04 SGD	0.03 SGD	0.02 SGD

	Sales per Share	EBIT per share	Earnings per Share
2010	0.04 SGD	0.03 SGD	0.02 SGD
2011	0.04 SGD	0.03 SGD	0.02 SGD
2012	0.04 SGD	0.03 SGD	0.02 SGD
2013	0.04 SGD	0.03 SGD	0.02 SGD
2014	0.05 SGD	0.04 SGD	0.03 SGD
2015	0.05 SGD	0.04 SGD	0.03 SGD
2016	0.05 SGD	0.04 SGD	0.03 SGD
2017	0.05 SGD	0.03 SGD	0.02 SGD
2018	0.05 SGD	0.03 SGD	0.02 SGD
2019	0.06 SGD	0.03 SGD	0.03 SGD
2020	0.05 SGD	0.02 SGD	0.02 SGD
2021	0.05 SGD	0.02 SGD	0.02 SGD
2022	0.06 SGD	0.03 SGD	0.02 SGD
2023	0.06 SGD	0.03 SGD	0.02 SGD
2024	0.06 SGD	0.02 SGD	0.03 SGD

	Number of stocks
2010	1.31 B Aktien
2011	1.31 B Aktien
2012	1.31 B Aktien
2013	1.31 B Aktien
2014	1.3 B Aktien
2015	1.31 B Aktien
2016	1.31 B Aktien
2017	1.31 B Aktien
2018	1.31 B Aktien
2019	1.31 B Aktien
2020	1.32 B Aktien
2021	1.33 B Aktien
2022	1.33 B Aktien
2023	1.33 B Aktien
2024	1.34 B Aktien

Date	Talkmed Group Dividend
2024	0.03 SGD
2023	0.02 SGD
2022	0.02 SGD
2021	0.01 SGD
2020	0.02 SGD
2019	0.02 SGD
2018	0.02 SGD
2017	0.02 SGD
2016	0.02 SGD
2015	0.02 SGD
2014	0.02 SGD

	Dividend	Dividend (Estimate)
2010	0 SGD	0 SGD
2011	0 SGD	0 SGD
2012	0 SGD	0 SGD
2013	0 SGD	0 SGD
2014	0.02 SGD	0 SGD
2015	0.02 SGD	0 SGD
2016	0.02 SGD	0 SGD
2017	0.02 SGD	0 SGD
2018	0.02 SGD	0 SGD
2019	0.02 SGD	0 SGD
2020	0.02 SGD	0 SGD
2021	0.01 SGD	0 SGD
2022	0.02 SGD	0 SGD
2023	0.02 SGD	0 SGD
2024	0.03 SGD	0 SGD

Date	Talkmed Group Payout ratio
2024	92.75 %
2023	97.18 %
2022	104.35 %
2021	76.72 %
2020	110.47 %
2019	75.92 %
2018	96.86 %
2017	77.97 %
2016	80.44 %
2015	82.57 %
2014	55.05 %
2013	97.18 %
2012	97.18 %
2011	97.18 %
2010	97.18 %

	Payout ratio
2010	97.18 %
2011	97.18 %
2012	97.18 %
2013	97.18 %
2014	55.05 %
2015	82.57 %
2016	80.44 %
2017	77.97 %
2018	96.86 %
2019	75.92 %
2020	110.47 %
2021	76.72 %
2022	104.35 %
2023	97.18 %
2024	92.75 %

%	Name	Stocks	Change	Date
64.16618 %	Ladyhill Holdings Pte. Ltd.	858,912,000	0	3/14/2024
7.42282 %	Khoo (Kei Siong)	99,360,000	0	3/14/2024
7.34035 %	Teo (Cheng Peng)	98,256,000	0	3/14/2024
3.54646 %	Lim (Hong Liang)	47,472,000	0	3/14/2024
0.46972 %	See (Hui Ti)	6,287,593	123,191	3/14/2024
0.36897 %	Lim (Bee Kok)	4,939,000	0	3/14/2024
0.16166 %	Quek (Hong Hui Richard)	2,163,951	664,529	3/14/2024
0.15091 %	Lai (Jason Justin)	2,020,000	0	3/14/2024
0.14633 %	Zee (Ying Kiat)	1,958,773	137,094	3/14/2024
0.11953 %	Chan (Jin Hoe)	1,600,000	0	3/14/2024
0.11206 %	Ng (Lin Chieh Kelvin)	1,500,000	0	3/14/2024
0.11206 %	Tan (Yii Hsien Barnabas)	1,500,000	0	3/14/2024
0.11206 %	Foo (Mei Ping)	1,500,000	0	3/14/2024
0.11038 %	Diong (Colin Phipps)	1,477,490	1,477,490	3/14/2024
0.10384 %	Sng (Su Ying Marian)	1,390,000	0	3/14/2024
0.09434 %	Thng (Yongxian)	1,262,800	-384,300	3/14/2024
0.09093 %	Wong (Chiung Ing)	1,217,216	1,217,216	3/14/2024
0.08353 %	Kok (Jaan Yang)	1,118,079	-58,916	3/14/2024
0.08220 %	Chandra Das S O Rajagopal Sitaram	1,100,300	0	1/21/2024
0.02241 %	Leong (Ching Ching)	300,000	0	1/21/2024
0.00448 %	Tan (Khai Tong)	60,000	60,000	1/1/2024

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
Citigroup	SupplierCustomer	-0,17	0,33	0,12	0,34	0,63
UOB-Kay Hian Holdings	SupplierCustomer	-0,29	0,65	0,18	0,21	-0,19

What values and corporate philosophy does Talkmed Group represent?

The values and corporate philosophy of Talkmed Group Ltd encompass a strong commitment to excellence in healthcare services. With a focus on patient-centric care, Talkmed Group Ltd strives to provide high-quality, comprehensive medical solutions. The company emphasizes professionalism, integrity, and innovation in its operations, aiming to deliver the best possible outcomes for patients. With a dedicated team of medical professionals and cutting-edge technology, Talkmed Group Ltd continuously seeks to enhance its services and expand its expertise, all while maintaining a patient-centered approach.

In which countries and regions is Talkmed Group primarily present?

Talkmed Group Ltd is primarily present in Singapore.

What significant milestones has the company Talkmed Group achieved?

Talkmed Group Ltd has achieved several significant milestones in its history. The company has successfully established itself as a leading provider of integrated oncology services in Singapore and the region. Talkmed Group Ltd has received numerous accolades and recognition for its dedication to delivering high-quality and comprehensive cancer care. The company has also built strong partnerships with key medical institutions and renowned oncologists, cementing its position as a trusted and reliable player in the field. With its commitment to innovation and patient-centric care, Talkmed Group Ltd continues to make strides in the oncology industry, driving positive outcomes for patients and their families.

What is the history and background of the company Talkmed Group?

Talkmed Group Ltd, a leading healthcare provider in Singapore, has an intriguing history and background. Established in 2005, the company was founded by Dr. Ang Peng Tiam, a renowned medical oncologist. Talkmed Group Ltd primarily focuses on the provision of specialized medical services, particularly in the field of oncology. Building upon their commitment to quality care, Talkmed Group Ltd has partnered with numerous local and international hospitals, enabling them to expand their reach and offer exceptional healthcare services to a broader patient base. With their team of highly qualified healthcare professionals and state-of-the-art facilities, Talkmed Group Ltd continues to make significant contributions to the medical industry, solidifying their position as a trusted name in healthcare.

Who are the main competitors of Talkmed Group in the market?

The main competitors of Talkmed Group Ltd in the market include Raffles Medical Group, Singapore Medical Group, and Q&M Dental Group.

In which industries is Talkmed Group primarily active?

Talkmed Group Ltd is primarily active in the healthcare industry.

What is the business model of Talkmed Group?

The business model of Talkmed Group Ltd involves providing integrated healthcare services, specializing in cancer treatment and medical oncology. As a leading medical group in Singapore, Talkmed focuses on delivering personalized and comprehensive care to patients, employing a multidisciplinary approach. The company collaborates with other healthcare providers and maintains close relationships with top hospitals and medical professionals. Talkmed offers a range of services such as clinical research, telemedicine, oncology training, and consultancy services. By combining advanced medical technology, research, and expertise, Talkmed Group Ltd aims to improve patient outcomes and enhance the quality of cancer care.

What is the P/E ratio of Talkmed Group 2025?

The P/E ratio cannot be calculated for Talkmed Group at the moment.

What is the P/S ratio of Talkmed Group 2025?

The P/S cannot be calculated for Talkmed Group currently.

What is the Quality Investing of Talkmed Group?

The Quality Investing for Talkmed Group is 7/10.

What is the revenue of Talkmed Group 2025?

The revenue cannot currently be calculated for Talkmed Group.

How high is the profit of Talkmed Group 2025?

The profit cannot currently be calculated for Talkmed Group.

What is the business model of Talkmed Group

The Talkmed Group Ltd is a publicly traded company based in Singapore. It operates in various areas of medicine, providing both clinical and diagnostic services. In addition, it specializes in the development of medical devices and technologies. Clinical services Talkmed is one of the leading cancer specialists in Asia, offering a wide range of clinical services including oncology, hematology, surgery, radiation therapy, cardiology, and neurology. These services are provided by experienced doctors and specialists who work closely with patients to achieve the best treatment outcomes. Diagnostic services Talkmed Group Ltd offers specialized diagnostic services such as pathology, radiology, and nuclear medicine. These services are crucial for detecting diseases and are therefore an important preventative measure. Development of medical devices and technology The company also specializes in developing medical devices and technologies to improve clinical and diagnostic services. One of its key products is the OncoSweep technology, which enables doctors to quickly and effectively detect cancer cells and tissues. Other products Talkmed also offers pharmaceutical products, either developed by third parties or produced by themselves. These products are used in combination with clinical and diagnostic services to provide better treatment outcomes for patients. Business model Talkmed Group Ltd's business model is based on providing high-quality clinical and diagnostic services. They strive to offer the best medical care by utilizing the latest technologies and procedures and employing experienced and qualified professionals. Talkmed Group earns its revenue by billing patients and insurance companies for the services provided. However, the company also aims to expand its presence in the market by participating in or acquiring other companies. It also has a strong presence in Southeast Asia, where there is great potential in the healthcare industry. In summary, Talkmed Group Ltd's business model is focused on providing high-quality clinical and diagnostic services to improve patients' lives. The company also has a strong commitment to developing new medical devices and technologies to enhance diagnostic accuracy and the effectiveness of clinical services. Talkmed Group Ltd will continue to grow in the future as there is a high demand in the healthcare industry.

What is the Talkmed Group dividend?

Talkmed Group pays a dividend of 0.02 SGD distributed over payouts per year.

How often does Talkmed Group pay dividends?

The dividend cannot currently be calculated for Talkmed Group or the company does not pay out a dividend.

What is the Talkmed Group ISIN?

The ISIN of Talkmed Group is SG2G61000003.

What is the Talkmed Group ticker?

The ticker of Talkmed Group is 5G3.SI.

How much dividend does Talkmed Group pay?

Over the past 12 months, Talkmed Group paid a dividend of 0.03 SGD . This corresponds to a dividend yield of about 6 %. For the coming 12 months, Talkmed Group is expected to pay a dividend of 0.03 SGD.

What is the dividend yield of Talkmed Group?

The current dividend yield of Talkmed Group is 6 %.

When does Talkmed Group pay dividends?

Talkmed Group pays a quarterly dividend. This is distributed in the months of May, September, May, September.

How secure is the dividend of Talkmed Group?

Talkmed Group paid dividends every year for the past 11 years.

What is the dividend of Talkmed Group?

For the upcoming 12 months, dividends amounting to 0.03 SGD are expected. This corresponds to a dividend yield of 6 %.

In which sector is Talkmed Group located?

Talkmed Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Talkmed Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Talkmed Group from 8/22/2024 amounting to 0.014 SGD, you needed to have the stock in your portfolio before the ex-date on 8/14/2024.

When did Talkmed Group pay the last dividend?

The last dividend was paid out on 8/22/2024.

What was the dividend of Talkmed Group in the year 2024?

In the year 2024, Talkmed Group distributed 0.024 SGD as dividends.

In which currency does Talkmed Group pay out the dividend?

The dividends of Talkmed Group are distributed in SGD.

Professional-grade financial intelligence

Price

Price

Ticker5G3.SI

ISINSG2G61000003

Talkmed Group stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Talkmed Group Stock Price History

Talkmed Group Revenue, EBIT, Net Income SG2G61000003 ·

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Talkmed Group Revenue, EBIT and net profit per share

Talkmed Group Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Talkmed Group stock margins SG2G61000003 ·

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Talkmed Group Margin History

Talkmed Group Stock Sales Revenue, EBIT, Earnings per Share SG2G61000003 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Talkmed Group Revenue, EBIT and net profit per share

Talkmed Group business model

Talkmed Group SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

The World’s Best Investors Are On Eulerpool

Talkmed Group Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Talkmed Group historical P/E ratio, EBIT multiple, and P/S ratio

The World’s Best Investors Are On Eulerpool

Talkmed Group shares outstanding SG2G61000003 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Talkmed Group stock splits

Talkmed Group dividend history and estimates SG2G61000003 ·

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

Talkmed Group Dividend History

Ticker
5G3.SI

ISIN
SG2G61000003